Live Webinar

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

Hosted by AJMC, Managed Healthcare Executive, Pharmacy Times and PBMI

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image
  • News
  • Watch
  • Journals
  • Conferences
  • Events
  • Resources
  • CE
  • About AJMC
  • Subscribe
Opinion|Videos|June 19, 2024

Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management

Medical experts highlight unmet needs in the PNH treatment landscape and considerations for utilizing eculizumab.

Episodes in this series

Video content above is prompted by the following:

  • Eculizumab was the first-in-class complement C5 inhibitor for PNH. Can you elaborate on the mechanism of action of eculizumab and its impact on the management of PNH?
  • Please elaborate on the persistent unmet needs in PNH management, such as residual intravascular hemolysis and C3-mediated extravascular hemolysis. How do they contribute to the treatment burden for patients?

Related Content